Brief: Monte Rosa Therapeutics Advances Second Development Candidate, Mrt-6160, For Treating Autoimmune Diseases
23/05/2023 12:32
May 23 (Reuters) - Monte Rosa Therapeutics Inc GLUE.O :
* MONTE ROSA THERAPEUTICS ADVANCES SECOND DEVELOPMENT
CANDIDATE,
MRT-6160, A NOVEL, HIGHLY SELECTIVE MOLECULAR GLUE DEGRADER
TARGETING VAV1 FOR THE TREATMENT OF AUTOIMMUNE DISEASES
* MONTE ROSA THERAPEUTICS INC - PLANNED IND FILING IN FIRST
HALF
OF 2024
* MONTE ROSA THERAPEUTICS INC-PRECLINICAL DATA SHOW
MRT-6160'S
ABILITY TO POTENTLY & SELECTIVELY DEGRADE VAV1 & INHIBIT DISEASE
PROGRESSION IN AUTOIMMUNITY MODELS
Source text for Eikon: ID:nGNX2PFY2P
Further company coverage: GLUE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Monte Rosa Therapeutics
See all newsBrief: Monte Rosa Therapeutics Announces Positive Results For Mrt-8102 In Gforce-1 Phase 1 Study Showing Normalization Of Key Pathogenic Drivers Of Ascvd In Subjects With Elevated Cvd Risk
Brief: Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Monte Rosa Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Monte Rosa Therapeutics Q2 revenue drops, net loss widens on higher R&D
Brief: Monte Rosa Therapeutics Q2 Collaboration Revenue USD 8.968 Million